Navigation Links
Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug
Date:12/2/2009

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a U.S. Oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

The licensing agreement encompasses the development and commercialization of TAR-1, a single-chain antibody fragment in preclinical development that may have an advantage in treating cancer patients because of its high specificity and affinity to binding mutant p53 protein.

Under the terms of the agreement, Champions has obtained the worldwide rights to TAR-1 and is responsible for the further development of the compound. Champions will utilize its Biomerk Tumorgraft(TM) platform technology to evaluate the activity of TAR-1 and determine the best path forward for the compound in regards to indication, patient population and potential drug combinations. Ramot will receive an upfront payment and will be eligible to receive milestone payments and royalties if Champions chooses to continue the license terms, which will be determined based on results from testing TAR-1 in the predictive Tumorgraft platform.

Inhibits tumor growth

Prof. Beka Solomon from Tel Aviv University identified that TAR-1 binds to and restores the wild-type active conformation of mutant p53 protein with a high degree of specificity, leading to in vivo inhibition of tumor growth. Given the frequency of mutant p53 in cancer, TAR-1 has the potential to target a wide range of human cancers.

"Licensing TAR-1 demonstrates the progression of our strategy to build our own Tumorgraft-driven pipeline of oncology drugs, which we expect to yield improved clinical development success rates," said Guy Malchi, Champions Biotechnology's Head of Corporate Development and International Operations.

"We were impressed by the potential of TAR-1 and we are planning to continue to in-license oncology drug candidates with compelling science and to develop only those with positive Tumorgraft results." TAR-1 will undergo Tumorgraft testing as Champions completes Tumorgraft testing of its other oncology drug, SG410, a tubulin inhibitor.

"We are excited to work with Champions Biotechnology. Their predictive platform and experienced scientific and clinical team make them an ideal candidate to move TAR-1 forward into the clinic and on the path to commercialization," said Dr. Ze'ev Weinfeld, CEO, Ramot at Tel Aviv University Ltd.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Houston Dermatologists to Round Up for Sun Safety at World-Class LPGA Tour Championship
2. World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center Champions of Life
3. Planned Parenthood Advocacy Project Los Angeles County Celebrates Champions of Choice at Politics, Sex & Cocktails
4. Maldonado Medical LLC Champions Physician & Patient Rights for Better Reimbursement Schedules Nationwide
5. Illinois Dermatologists Tee Up for Sun Safety at Two World-Class Golf Championships
6. Mentors Who Support Students Receive TCWF Champions of Health Professions Diversity Award
7. The Byron Nelson: Championship Philosophy, Timeless Excellence
8. Champions Shawn Johnson & Phil Jackson Wear Energy Muse Jewelry
9. The Biggest Loser Champions Living Well
10. Insulet Applauds Employee for Bronze Medal Performance in World Blind Sailing Championships
11. The National Multiple Sclerosis Societys 35th Annual Dinner of Champions to Honor Summit Entertainments Rob Friedman
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology: